EFFECT OF CYP2C9 AND VKORC1 GENE POLYMORPHISM ON WARFARIN STEADY-STATE THERAPEUTIC DOSE AND INDIVIDUAL ANTICOAGULATION EFFICACY
Kou Huijuan,Qiangsun Zheng,Jie Deng
DOI: https://doi.org/10.13753/j.issn.1007-6611.2017.11.004
IF: 4.9
2018-01-01
Journal of Hypertension
Abstract:Objective To explore the effect of CYP2C9 and VKORC1 gene polymorphism on warfarin steady-state therapeutic dose and individual anticoagulation therapy in patients with non-valvular atrial fibrillation.Methods The subjects with non-valvular atrial fi brillation were enrolled from cardiovascular clinic and in-patient wards from June 2015 to March 2017.After using the CHA2DS2-VASc and HAS-BLED system to evaluate the risks of stroke and bleeding,the patients with oral anticoagulant therapy were divided into con ventional group(initial dose of 1.5-3.0 mg/d) and individual group(the individualized recommended treatment dose of warfarin based on CYP2C9 and VKORC1 genotyping).The genotype and allele frequency of CYP2C9 and VKORC1,the time required for INR 2.0-3.0 after taking warfarin,association between individualized recommended treatment dose and warfarin steady-state therapeutic dose,and the incidence of drug-related side effects in individual group and conventional group were explored in the clinical study.All data were analyzed using SPSS 13.0 software.Results A total of 678 participants were enrolled into the study,and 134 patients received the oral anticoagulant therapy finally.The age (P =0.016),individualized recommended treatment dose (P ＜ 0.001) and the time required for INR 2.0-3.0 after taking warfarin (P ＜ 0.001) were significantly different between individual group and conventional group.The CYP2C9 * 2(R144C,C ＞T) genotyping showed that the allele frequencies of CC,CT and TT were 100％,0％ and 0％,respectively.CYP2C9 * 3 (I359L,A ＞ C) genotyping showed that the allele frequencies of AA,AC and CC were 95.7％,4.3％ and 0％,respectively.VKORC1 (1639,G ＞ A) genotyping showed that the allele frequencies of GG,GA and AA were 0％,17.4％ and 82.6％,respectively.The warfarin dose was (3.24 ±0.91) mg/d in CYP2C9 * 2 CC,(3.31 ±0.90)mg/d and (2.24 ±0.16)mg/d in CYP2C9 * 3-I359L AA and AC,(3.81 ± 1.34) mg/d and (3.10 ±0.75) mg/d in VKOR C1-1639 GA and AA,respectively.The warfarin steady-state therapeutic dose was negatively with age(r =-0.589,P ＜ 0.001),but positively with height (r =0.384,P =0.033) and individualized recommended treatment dose(r =0.935,P ＜ 0.001).After adjusting for confounders via multivariate linear regression,the age,genotype of CYP2C9 * 3 and VKORC1 values remained independently associated with warfarin steady-state therapeutic dose for patients receiving oral anticoagulantion.No drug-related thromboembolism and haemorrhage were observed in two groups.Conclusion CYP2C9 and VKORC1 gene polymorphism can help to shorten the standard time,predict the warfarin steadystate treatment dose and optimize the therapeutic strategies of oral anticoagulant therapy in patients with non-valvular atrial fibrillation.